Please provide your email address to receive an email when new articles are posted on . Younger patients who received higher doses of tisagenlecleucel for advanced B-cell acute lymphoblastic leukemia ...
CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...
SOUTH SAN FRANCISCO, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...
Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif., Oct. 15, 2024 /PRNewswire ...
Presentations on the first day of the 2023 American Society of Clinical Oncology Annual Meeting covered data on a split dose CAR T-cell therapy and a CAR T therapy manufactured with TKI. Less than a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results